Abstract
Vidarabine has been used for the treatment of patients with local and systemic herpes virus infection; moreover, it was recently reported that it inhibits cardiac type 5 adenylyl cyclase. Furthermore, vidarabine has been shown to suppress atrial fibrillation and improve congestive heart failure in experimental models of mice induced by the isoproterenol infusion. Since information that can explain its experimentally demonstrated efficacy against congestive heart failure and atrial fibrillation remains limited, in this study we precisely assessed cardio-electropharmacological effect using the halothane-anesthetized canine model. Vidarabine was intravenously administrated in three escalating doses of 1, 10, 100 mg/kg over 10 min with a pause between the doses (n = 4). Meanwhile, the vehicle dimethyl sulfoxide in volumes of 0.033, 0.033 and 0.33 mL/kg was intravenously administrated in the same manner as was vidarabine (n = 4). No significant difference was detected in any cardiohemodynamic or electrophysiological variables between the vehicle- and vidarabine-treated groups, which indicates that effective doses of vidarabine adequately inhibiting type 5 adenylyl cyclase did not affect the cardiovascular variables in vivo at all, s...Continue Reading
References
Nov 1, 1989·Journal of Pharmacological Methods·A Van de WaterR S Reneman
Jun 6, 2002·Japanese Journal of Pharmacology·Atsushi Sugiyama, Keitaro Hashimoto
Sep 13, 2002·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroshi YoshidaKeitaro Hashimoto
Jul 19, 2003·Circulation Research·Satoshi OkumuraYoshihiro Ishikawa
Jul 21, 2004·The Journal of Biological Chemistry·Kousaku IwatsuboYoshihiro Ishikawa
Dec 16, 2004·Journal of Pharmacological Sciences·Atsushi SugiyamaKeitaro Hashimoto
May 27, 2008·Circulation Journal : Official Journal of the Japanese Circulation Society·Tomomichi IshizakaAtsushi Sugiyama
Jun 17, 2008·British Journal of Pharmacology·A Sugiyama
Jul 24, 2010·British Journal of Pharmacology·J C McGrathC L Wainwright
Jul 24, 2010·British Journal of Pharmacology·Carol KilkennyUNKNOWN NC3Rs Reporting Guidelines Working Group
Aug 4, 2010·Cardiovascular Toxicology·Yoshitaka MitsumoriAtsushi Sugiyama
Dec 2, 2010·Advances in Experimental Medicine and Biology·Clara Thompson, Richard Whitley
Mar 20, 2012·Osteoarthritis and Cartilage·C KilkennyD G Altman
Apr 17, 2012·American Journal of Physiology. Heart and Circulatory Physiology·Kosaku IwatsuboYoshihiro Ishikawa
Feb 20, 2013·Cardiovascular Toxicology·Ken KitaharaAtsushi Sugiyama
Jul 11, 2013·PloS One·Joerg H BraeunigRoland Seifert
Jan 7, 2015·The Journal of Toxicological Sciences·Yukiko Yamazaki-HashimotoAtsushi Sugiyama
Citations
Mar 5, 2016·The Journal of Pharmacology and Experimental Therapeutics·Claudio A BravoStephen F Vatner
Nov 8, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Takashi NakamuraYoshihiro Ishikawa
Feb 18, 2018·Pflügers Archiv : European journal of physiology·Kenji SuitaYoshihiro Ishikawa
Mar 4, 2017·Pharmacological Reviews·Carmen W DessauerRoland Seifert
Mar 21, 2020·Cardiovascular Toxicology·Yoshiki KondoAtsushi Sugiyama
Mar 13, 2018·Frontiers in Physiology·Joanne J A van BavelMarcel A G van der Heyden